Epsilon M&A Deal Report - Noden Pharma Designated Activity Company
Transaction Multiples for the Valuation of Private Companies
Private Group led by Stanley Capital / Noden Pharma Designated Activity Company
No EMAT :
102415
Announced Date :
30/07/2020
Type :
LBO (Leverage Buy Out)
Deal Value :
Yes
Acquirer :
Private Group led by Stanley Capital
Target :
Noden Pharma Designated Activity Company
Country :
Ireland
Sector of activity :
- Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
Business Description :
Noden Pharma Designated Activity Company operates as a global specialty pharmaceutical company focused on acquiring prescription medicines across a range of therapeutic areas notably to the...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|||||
| Current |
Rating :
*
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
| Date | Acquirer | Target | Country | Multiples | See details |
| 21/09/2020 | Roche | Inflazome | Ireland | * | 102408 |
| 28/11/2016 | Private group led by Ardian | SCHWIND eye-tech-solutions | Germany | ** | 101735 |
Source: Epsilon Research / EMAT
